![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, February 05, 2015 10:37:15 AM
Oxford will manufacture several batches of a lentiviral vector used to deliver Novartis' CTL019 technology. This is an experimentat immunotherapy program Novartis recently licensed from the University of Pennsylvania. It is currently in Phase 1/2 trials to treat various B cell cancers (eg relapsed leukemia in children) and the approach uses patients' own T cells, which are removed and engineered using the Lentivector approach to recognise cancerous B cells more effectively. The cells are then re-infused into patients, where they now attack the cancer (an autologous treatment approach).
It appears to us that the University of Pennsylvania likely used Oxford's intellectual property in its early stage trials and that now it is progressing as a commercial program with Novartis, Oxford's intellectual property is locked in. Oxford will manufacture the engineered viruses for next Phase 2 trials of the program. Novartis purchased one of Dendreon's Provenge facilities in late 2012, which we assume is handling the next step, to treat patients autologous T calls with the engineered virus and grow them up. In the final step these are then put back into patients and are now engineered to recognise and remove cancerous B cells.
Some very promising early results have been seen with the program, including two complete responses published a fortnight ago in the New England Journal of Medicine.
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Mawson Finland Provides Update on Exploration Activities at Rajapalot • MFL • Aug 21, 2024 9:06 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM